| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 2 Apr 2025 | 26 Mar 2025 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/04/2025 inter alia to consider and approve the First Call money Notice on the partly paid Equity Shares issued on Rights basis which is to be sent to the eligible Shareholders Solara Active Pharma Sciences Limited informed the exchange about the outcome of the Rights Issue Committee Meeting held today (i.e.) April 02, 2025 interalia to consider and approve the First call money notice to be sent to the eligible shareholders Outcome: Solara Active Pharma Sciences Limited informed the exchange about the Rights Issue Committee Meeting held today (i.e.) on April 02, 2025 interalia to consider and approve the First call money notice to be sent to the eligible shareholders (As per BSE Announcement Dated on 02/04/2025) | ||
| Board Meeting | 26 Mar 2025 | 20 Mar 2025 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2025 inter alia to consider and approve the proposal of making First Call on 11998755 partly paid-up Equity Shares having a face value of Rs.10/- each (Rs.3.50/- paid-up) issued by the Company on rights basis in their Rights Issue Committee Meeting. Solara Active Pharma Sciences Limited had informed the Exchange that Rights Issue Commitee Meeting of the Board of Directors at its meeting held on March 26, 2025, has approved the making of first call of Rs. 3.50/- each (i.e.) 35% on the face value of Rs. 10/- each on the outstanding 1,19,98,755 partly paid up equity shares of the Company which were allotted on June 19, 2024 on a rights basis and fixation of Record date, tendering period and other matters Solara Active Pharma Sciences Limited has informed the Exchange that Board of Directors at its meeting held on March 26, 2025, has approved the making of first call of Rs. 3.50/- each (i.e.) 35% on the face value of Rs. 10/- each on the outstanding 1,19,98,755 partly paid-up equity shares of the Company which were allotted on June 19, 2024 on a right basis, fixation of Record date, Tendering period and other matters. Solara Active Pharma Sciences Limited has informed the exchange about the Record date for the purpose of making first call for the shares issued on Rights Basis. (As Per BSE Announcement Dated on 26.03.2025) | ||
| Board Meeting | 21 Feb 2025 | 21 Feb 2025 |
| Solara Active Pharma Sciences Limited has informed the Exchange regarding Appointment and Resignation of Chief Executive officer, Appointment and Resignation of Chief Financial Officer, Appointment of a Senior Managerial Personnel. | ||
| Board Meeting | 24 Jan 2025 | 16 Jan 2025 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve Solara Active Pharma Sciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31 2024 and other matters. Solara Active Pharma Sciences Limited has informed the Exchange regarding Board meeting held on January 24, 2025 interalia to consider and approve the Unaudited Financial Results for the quarter ended December 31, 2024 and other matters. (As Per BSE Announcement Dated on: 24/01/2025) | ||
| Board Meeting | 21 Oct 2024 | 14 Oct 2024 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30 2024 and other matters SOLARA : Solara Active Pharma Sciences Limited has informed the Exchange regarding Board meeting held on October 21, 2024 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 and allotment of 49,000 Equity shares pursuant to exercise of ESOP Grant under SOLARA ESOP Plan ,2018. Read less.. Solara Active pharma Sciences Limited has informed the Exchange regarding Board meeting held on October 21, 2024 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 and allotment of 49,000 equity shares pursuant to exercise of ESOP granted under SOLARA ESOP Plan 2018 Read less.. (As Per BSE Announcement Dated on 21.10.2024) | ||
| Board Meeting | 22 Jul 2024 | 15 Jul 2024 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2024 inter alia to consider and approve unaudited financial results for the quarter ended June 30 2024. Unaudited financial results for the quarter ended June 30, 2024 (As per BSE Announcement Dated on 22/07/2024) | ||
| Board Meeting | 29 May 2024 | 21 May 2024 |
| Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31 2024. Results for the period ended March 31, 2024 Outcome of Board Meeting (As Per BSE Announcement Dated on 29.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
